


# Carbon Nanotubes in Medicine

where we are and where we need to be





*Scientific American* October 2003



Center for Biological  
and Environmental Nanotechnology  
Rice University

Charlie Johnson Group, University of Pennsylvania



Michigan Center for Biological Nanotechnology  
University of Michigan

Valerie C. Moore  
University of Texas Health Science Center at Houston

# Carbon Nanotubes in Medicine

## where we are and where we need to be

---

- Carbon Nanotubes in Medicine
  - Motivation
  - Applications
    - MRI Contrast Agents
    - Radical Scavenging Formulations
- Carbon Nanotube Behavior In Vitro and In Vivo
  - Brief Review
  - Highlight Progress in Characterization
  - Examples of Refined Research
- Standards Needs for Biomedical Research

# Versatility of Nanotubes

## Covalent Sidewall Functionalization

solubility  
matrix incorporation  
attachment of targets and therapeutics  
quenches NIRF, usually

## Filling

CT contrast imaging –  $I_2$   
MR contrast imaging –  $Gd^{3+}$   
cell tracking  
carry cargo

## Covalent End Functionalization


solubility  
matrix incorporation  
attachment of targets and therapeutics  
allows NIRF with  $L > 100$  nm

## Inherent NIRF

contrast imaging  
cell tracking  
thermal ablation  
biomolecule detection

## Non-Covalent Sidewall Functionalization

solubility  
matrix incorporation  
attachment of targets and therapeutics  
allows NIR fluorescence and ablation



# Carbon Nanotube Impact on Medicine

- Administration/Implantation
  - Material Engineering
    - strength enhancement
    - electrical
  - Contrast Agents
    - inherent NIR
    - filling
  - Therapeutic Agents
    - ablation
    - drug attachment
    - radical scavenging
- Devices
  - monitor biomolecule levels
- Environmental Health and Safety
  - occupational exposure

---

# Therapeutic Agents

## Radical Scavenging Formulations

---


# Radiation-Induced Oxidative Stress

Target 1: Extracellular ROS induced by direct radiation (A).

Target 2: Cellular ROS (C,D).



Target 3: Autocrine secondary ROS (E).

Target 4: Paracrine secondary ROS (F).




# Carbon Nanomaterial Radioprotectors


## Zebrafish Morphological Changes with Radiation Exposure



## Efficacy of DF-1 at only 100 $\mu$ M







DF-1 was added 3 h prior to IR at 24 hpf  
Morphology was assessed either 3 d (20 Gy) or 6 d (40 Gy) post fertilization





# Oxygen Radical Absorbance Capacity

- Radical
  - AAPH thermal initiation
- Radical Scavenger
  - Trolox – assay comparison
  - Amifostine – gold standard
- Indicator
  - Fluorescein



- Calculate Antioxidant Capacity in Trolox Equivalents


$$\text{relative ORAC value} = \frac{[(AUC_{\text{Sample}} - AUC_{\text{Blank}}) / (AUC_{\text{Trolox}} - AUC_{\text{Blank}})] \times (\text{molarity of Trolox} / \text{molarity of sample})}$$






# Carbon Nanomaterial Radioprotectors


## Cell-Free ORAC Assay




Trolox



Covalent PEG – Ionic BHT



Pluronic Coated – Covalent BHT





DF-1  
dendrite fullerene 1


Compound	Trolox Equivalents
DF-1	5
Pluronic Suspended SWCNT Covalent BHT	600
Covalently PEGylated SWCNT Ionic BHT	2400

# Carbon Nanomaterial Radioprotectors

## In Vitro Micronuclei Assay



<u>Radiation</u>	<u>DF-1</u>	<u>+MN</u>	<u>-MN</u>	<u>%MN</u>
0	-	1	521	0.19
0	+	2	567	0.35
2	-	55	688	7.40
2	+	29	668	4.16



---

# Carbon Nanotube Behavior In Vitro and In Vivo

---

# Biodistribution Literature



- 2004 – Wang, et al. investigated the biodistribution of hydroxylated SWCNTs in mice

- Nanotube Characterization

- “purity” via Raman and TEM
- length via laser scattering
  - 280-450 nm
- concentration via UV-vis absorbance spectroscopy
- biodistribution via  $^{125}\text{I}$  labeling

- Findings

- 80% excreted within 11 days
  - 94% urine, 6% feces
- bone > kidney > stomach




- 2005 – Radomski, et al. investigated nanoparticle-induced vascular thrombosis

- Nanotube Characterization

- purchased purified, no independent characterization

- Findings

- MCN > SWCNT > MWCNT > standard urban particulate matter induced vascular thrombosis
- $\text{C}_{60}$  did not induce thrombosis



# Biodistribution Literature


- 2006 – Singh, et al. investigated biodistribution of ammonium functionalized SWCNT and MWCNT

- Nanotube Characterization

- “purity” from manufacturer
    - diameter from manufacturer
      - ~ 1 nm SWCNT, no distribution given
      - 20-30 nm MWCNT, no distribution given
    - length from manufacturer
      - 300-1000 nm SWCNT, no distribution given
      - 500-2000 nm MWCNT, no distribution given
    - mention in-solution physical characteristics will be different than bulk measurements above
    - biodistribution via  $^{111}\text{In}$  labeling

- Findings

- kidney > muscle > skin > bone ...
    - 3-3.5 hr half life
    - no acute toxicity



# Biodistribution Literature

- 2007 – Guo, et al, investigated biodistribution and clearance of glucosamine functionalized MWCNT

- Nanotube Characterization

- measurements made throughout process MWCNTs

- as-received
- purified
- functionalized

- “purity” via TGA and ICP-MS

- as-received
  - > 95% MWCNT
  - < 3% amorphous carbon
  - 0.6% Ni
- Purified
  - > 96% MWCNT
  - < 0.2% Ni

- diameter and length via TEM



- 20-40 nm diameter and tens of microns long

- functionalization confirmation via FTIR

- biodistribution via  $^{99m}\text{Tc}$  labeling

- Findings

- 5 hr half-life
- excretion via urine and feces, roughly 50:50



---

# Standards Needed

---

# Standards Needed

- Standard Samples
  
- Standard Characterization Protocols
  1. Composition
    - Catalyst Content
    - Non-NT Carbon
    - Carbon Nanotube Content
  2. Aspect Ratio/Length
  3. Solution Concentration
  4. Surface Functionalization
    - surface charge per unit length
    - degree of functionalization



# Acknowledgements

- UT-HSC at Houston
  - ❑ Pratixa Joshi, MS
  - ❑ Melinda Lackey, MS
  - ❑ Thomas Seiter
  - ❑ Ellen Bleiweiss
  - ❑ Melissa Schmidt
  
  - ❑ Jodie L. Conyers, PhD
  - ❑ S. Ward Casscells, MD
  - ❑ Ranga Partha, PhD
- Thomas Jefferson University
  - ❑ Adam Dicker, MD PhD
  - ❑ Ulrich Rodeck, MD
- Funding
  - ❑ US Army – Telemedicine and Advanced Technology Research Center
  - ❑ NASA
  - ❑ NanoHealth Alliance
- NASA-JSC
  - ❑ Janice Huff, PhD
  - ❑ Honglu Wu, PhD
  - ❑ Rachael Casey, PhD
  - ❑ Julia Reynolds
  - ❑ Madeline Burgoyne
  - ❑ Kelley Waterhouse
- Rice University
  - ❑ James Tour, PhD
    - Dimtry Kosynkin, PhD
    - Ashley Leonard
    - Katherine Price
    - Rebecca Lucente-Schultz

